{"id":754985,"date":"2023-05-04T10:41:16","date_gmt":"2023-05-04T14:41:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharmas-real-world-healthcare-utilization-data-comparing-gimoti-to-oral-metoclopramide-to-be-presented-at-digestive-disease-week-ddw-2023\/"},"modified":"2023-05-04T10:41:16","modified_gmt":"2023-05-04T14:41:16","slug":"evoke-pharmas-real-world-healthcare-utilization-data-comparing-gimoti-to-oral-metoclopramide-to-be-presented-at-digestive-disease-week-ddw-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharmas-real-world-healthcare-utilization-data-comparing-gimoti-to-oral-metoclopramide-to-be-presented-at-digestive-disease-week-ddw-2023\/","title":{"rendered":"Evoke Pharma\u2019s Real-World Healthcare Utilization Data Comparing GIMOTI\u00ae to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023"},"content":{"rendered":"
\n

\n Compelling data elevated to distinguished DDW oral plenary session<\/em>
\n \n <\/p>\n

\n GIMOTI to be showcased in additional activities at conference <\/em>\n <\/p>\n

SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Evoke Pharma, Inc.\u00a0(NASDAQ: EVOK),<\/a>\u00a0a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae<\/sup>\u00a0(metoclopramide) nasal spray,\u00a0announced that the abstract entitled \u201cReducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide\u201d will be presented at Digestive Disease Week (DDW) 2023 taking place from May 6-9, 2023 at the McCormick Place, Chicago.<\/p>\n

David C. Kunkel, MD, Gastroenterologist and Associate Professor of Medicine at University of California San Diego Health, will deliver an oral presentation of the abstract in the AGA Clinical Practice Section Distinguished Abstract Plenary Session at DDW on Tuesday, May 9th<\/sup> at 8:20 AM CDT. The oral presentation will focus on the impact of GIMOTI to reduce healthcare resources across several settings, such as physician’s offices visits, emergency room visits, and inpatient and outpatient hospital stays from a retrospective analysis of 514 diabetic gastroparesis patients compared those receiving oral metoclopramide.<\/p>\n

Plenary sessions at DDW are the forum for highlighting the year\u2019s best research abstracts that have the potential to impact clinical practice and make a significant contribution to the field of gastroenterology, as determined by the conference organizers.\u00a0These real-world data were selected for presentation alongside a total of only six (6) meritorious clinical abstracts from more than 3,500 that were submitted.<\/p>\n

GIMOTI is the first and only FDA-approved nasal formulation of metoclopramide commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent DGP. By bypassing the stomach and being directly absorbed in the bloodstream, GIMOTI may provide relief to patients experiencing acute and recurrent flares, especially nausea, vomiting and abdominal pain, which can result in increased visits to their doctors and reliance on costly emergent care (emergency department visits and hospitalizations).<\/p>\n

An additional poster presentation entitled \u201cUse of Machine Learning to Identify Gastroparesis Patient Suitable for Nasal Spray Metoclopramide\u201d will be presented by Pierantonio Russo, MD, Chief Medical Officer of EVERSANA. This study used large claims databases and clinical features of GIMOTI-prescribed patients to predictively model patients in the US who might be appropriate for GIMOTI based on having similar clinical features.<\/p>\n

In addition, Evoke Pharma will showcase their GIMOTI nasal spray and supporting educational materials at DDW booth #3334. <\/strong>Evoke encourages all attendees to visit their booth for additional discussion to learn more about the product and its impact on patients.<\/p>\n

\n Details of the presentations are as follows:<\/strong>
\n
1.\u00a0\u00a0\u00a0AGA Distinguished Plenary Presentation Title:<\/strong> \u201cReducing Real-World Healthcare Resource Utilization for Patients with Diabetic Gastroparesis (DGP)
\u00a0 \u00a0 \u00a0 Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide\u201d<\/p>\n

\n Presentation Date & Time:<\/strong>\u00a0May 9, 2023, from\u00a08:00 AM to 9:30 AM CDT<\/p>\n

\n Presenter:<\/strong> Dr.\u00a0David C. Kunkel, Gastroenterologist and Associate Professor of Medicine at\u00a0UC San Diego Health<\/p>\n

\n Location:<\/strong>\u00a0McCormick Place,\u00a0Chicago, IL<\/p>\n

2.\u00a0\u00a0\u00a0Poster Presentation Title<\/strong>: \u201cUse of Machine Learning to Identify Gastroparesis Patient Appropriate for Nasal Spray Metoclopramide\u201d (Poster Number<\/strong>:
\u00a0 \u00a0 \u00a0 Su1651)<\/p>\n

\n Session Date and Time<\/strong>: May 7, 2023 from 12:30 PM to 1:30 PM CDT<\/p>\n

\n Presenter:<\/strong> Pierantonio Russo, MD, Corporate Chief Medical Officer, EVERSANA<\/p>\n

\n Location:<\/strong>\u00a0McCormick Place,\u00a0Chicago, IL<\/p>\n

\n About\u00a0Evoke Pharma, Inc.<\/strong>
\n
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in\u00a0the United States\u00a0to treat gastroparesis.<\/p>\n

Follow GIMOTI on Facebook<\/a>
Follow\u00a0Evoke Pharma\u00a0on Facebook<\/a>
Follow\u00a0Evoke Pharma\u00a0on LinkedIn<\/a>
Follow Evoke Pharma on Twitter<\/a><\/p>\n

\n About Gimoti\u00ae<\/sup> (metoclopramide) nasal spray<\/strong>
\n
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.<\/p>\n

\n Important Safety Information<\/strong>
\n
WARNING: TARDIVE DYSKINESIA<\/p>\n